Research programme: antibody-drug conjugates - Advanced Proteome Therapeutics/ Heidelberg Pharma Research

Drug Profile

Research programme: antibody-drug conjugates - Advanced Proteome Therapeutics/ Heidelberg Pharma Research

Latest Information Update: 10 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advanced Proteome Therapeutics; Heidelberg Pharma
  • Developer Advanced Proteome Therapeutics; Heidelberg Pharma Research
  • Class Antibacterials; Drug conjugates; Immunoconjugates
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 08 Jan 2018 Preclinical trials in Cancer in USA and Germany (Parenteral)
  • 09 Oct 2017 Heidelberg Pharma is now called Heidelberg Pharma Research
  • 19 Dec 2016 USPTO issues notice of allowance covering APC's technology involving specific proteins that have been attached (linked) to other proteins and exhibit activity against tumour cells
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top